Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 2-(dimethylamino)-1-((2-(3-methoxyphenyl)phenoxy)methyl)ethyl Hydrogensuccinate Hydrochloride
2. Mci 9042
3. Mci-9042
4. Mono-(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl)succinate Hydrochloride
5. Sarpogrelate
1. 135159-51-2
2. Sarpogrelate Hcl
3. Anplag
4. Mci-9042
5. Mci 9042
6. Sarpogrelate (hydrochloride)
7. Sarpogrelate Hydrochloride [jan]
8. Sarpogrelatehydrochloride
9. Fqn8n8qp1b
10. C24h32clno6
11. Dsstox_rid_81804
12. Dsstox_gsid_46662
13. Chembl541829
14. 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic Acid;hydrochloride
15. Butanedioic Acid, Esters, Mono(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl) Ester, Hydrochloride, (+-)-
16. Cas-135159-51-2
17. Dsstox_cid_26662
18. 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic Acid Hydrochloride
19. Butanedioic Acid 1-[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] Ester Hydrochloride
20. Butanedioic Acid, Mono(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl) Ester, Hydrochloride, (+-)-
21. Ncgc00167489-01
22. Ncgc00167489-03
23. Unii-fqn8n8qp1b
24. Anplag (tn)
25. Mfcd00887582
26. Schembl120568
27. Dtxsid8046662
28. Chebi:32122
29. Amy8866
30. Sarpogrelate Hydrochloride- Bio-x
31. Sarpogrelate Hydrochloride (jp17)
32. Bcp07360
33. Tox21_112490
34. S3706
35. Akos015889582
36. Tox21_112490_1
37. Ac-1598
38. Ccg-269415
39. H59s512
40. Ks-5244
41. (+/-)-sarpogrelate Hydrochloride
42. Bs164394
43. Hy-10564
44. Sarpogrelate Hydrochloride [who-dd]
45. Ls-187118
46. Sarpogrelate Hydrochloride, >=98% (hplc)
47. Ft-0602637
48. Sarpogrelate Hydrochloride, (+/-)-
49. D01624
50. A806893
51. J-006654
52. Q27278133
53. 4-((1-(dimethylamino)-3-(2-(3-methoxyphenethyl)phenoxy)propan-2-yl)oxy)-4-oxobutanoic Acid Hcl
54. 4-(1-(dimethylamino)-3-(2-(3-methoxyphenethyl)phenoxy)propan-2-yloxy)-4-oxobutanoic Acid Hydrochloride
55. 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxidanylidene-butanoic Acid Hydrochloride
56. 4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic Acid Hydrochloride
57. Butanedioic Acid, 1-(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl) Ester, Hydrochloride (1:1)
58. Butanedioic Acid, Mono(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl) Ester, Hydrochloride
59. Butanedioic Acid, Mono(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl) Ester, Hydrochloride, (+/-)-
60. Succinic Acid Mono-(1-dimethylaminomethyl-2-(2-[2-(3-methoxyphenyl)ethyl]phenoxy)ethyl) Ester Hydrochloride
Molecular Weight | 466.0 g/mol |
---|---|
Molecular Formula | C24H32ClNO6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 14 |
Exact Mass | 465.1918154 g/mol |
Monoisotopic Mass | 465.1918154 g/mol |
Topological Polar Surface Area | 85.3 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 540 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
Serotonin Antagonists
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
74
PharmaCompass offers a list of Sarpogrelate Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sarpogrelate Hydrochloride manufacturer or Sarpogrelate Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sarpogrelate Hydrochloride manufacturer or Sarpogrelate Hydrochloride supplier.
PharmaCompass also assists you with knowing the Sarpogrelate Hydrochloride API Price utilized in the formulation of products. Sarpogrelate Hydrochloride API Price is not always fixed or binding as the Sarpogrelate Hydrochloride Price is obtained through a variety of data sources. The Sarpogrelate Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Anplag manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Anplag, including repackagers and relabelers. The FDA regulates Anplag manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Anplag API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Anplag manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Anplag supplier is an individual or a company that provides Anplag active pharmaceutical ingredient (API) or Anplag finished formulations upon request. The Anplag suppliers may include Anplag API manufacturers, exporters, distributors and traders.
click here to find a list of Anplag suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Anplag Drug Master File in Japan (Anplag JDMF) empowers Anplag API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Anplag JDMF during the approval evaluation for pharmaceutical products. At the time of Anplag JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Anplag suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Anplag Drug Master File in Korea (Anplag KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Anplag. The MFDS reviews the Anplag KDMF as part of the drug registration process and uses the information provided in the Anplag KDMF to evaluate the safety and efficacy of the drug.
After submitting a Anplag KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Anplag API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Anplag suppliers with KDMF on PharmaCompass.
Anplag Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Anplag GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Anplag GMP manufacturer or Anplag GMP API supplier for your needs.
A Anplag CoA (Certificate of Analysis) is a formal document that attests to Anplag's compliance with Anplag specifications and serves as a tool for batch-level quality control.
Anplag CoA mostly includes findings from lab analyses of a specific batch. For each Anplag CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Anplag may be tested according to a variety of international standards, such as European Pharmacopoeia (Anplag EP), Anplag JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Anplag USP).